Skip to main
NKTX
NKTX logo

Nkarta, Inc. (NKTX) Stock Forecast & Price Target

Nkarta, Inc. (NKTX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nkarta Inc is positioned as a promising investment opportunity within the emerging field of engineered cell-based therapies for cancer, primarily due to its innovative approach harnessing the natural power of NK cells. The company's decision to reincorporate standardized lymphodepletion with fludarabine has significantly enhanced patient enrollment, while strategic management changes, including the addition of a new Chief Medical Officer, are expected to support ongoing clinical development. The fundamental advantages of NK cell therapies over traditional CAR-T therapies highlight Nkarta's potential to overcome existing limitations in cancer treatment, further bolstering a favorable outlook for the company's future growth and valuation.

Bears say

Nkarta Inc's financial outlook is negatively impacted by a sequential decline in both research and development (R&D) and selling, general, and administrative (SG&A) expenditures, with R&D spending dropping 14% and SG&A down 48%, which may indicate constraints in operational capacity and strategic investment. The upcoming May 2025 protocol amendment, which aims to reintegrate fludarabine into the NKX019 treatment regimen, could limit the effectiveness of conclusions drawn from initial clinical disclosures due to a likely narrow patient cohort. Additionally, management's choice to delay a preliminary year-end 2025 data release in favor of a comprehensive dataset presentation in FY26 raises concerns about transparency and the potential inconclusiveness of the forthcoming results, suggesting increased uncertainty surrounding the company's clinical progress and its impact on future performance.

Nkarta, Inc. (NKTX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nkarta, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nkarta, Inc. (NKTX) Forecast

Analysts have given Nkarta, Inc. (NKTX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Nkarta, Inc. (NKTX) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nkarta, Inc. (NKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.